Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Trial Information
Current as of September 09, 2025
Recruiting
Keywords
ClinConnect Summary
This study is a Phase Ib, open-label, multicentre study of SYN818 with Olaparib administered orally in patients with locally advanced or metastatic solid tumors harboring mutations in BRCA and/or defects in the homologous recombination repair (HRR) pathway
Gender
ALL
Eligibility criteria
About
No description available.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported